Weight, GLP-1s and Obesity Medicine
GLP-1 medicines are now approved for heart, sleep and liver outcomes, which changes who should take one and for how long.
No question matches that. Search the whole library.
Before you start5
- Do I qualify for a GLP-1 medication? What the approved BMI thresholds are, and why meeting them is only the beginning of the assessment
- Who should not take a GLP-1 medication? The contraindications on the label, plus the clinical situations that should stop a prescription before it starts
- Is BMI a useful number for me? What a single number can and cannot tell you, and the measurement recommended alongside it now
- When is weight gain a medical problem rather than a calorie problem? Signals that weight gain deserves a workup, including the medications and conditions commonly missed behind it
- Why does weight come back after I lose it? Why regain is a physiological response rather than a character failure, and what shifts after weight loss
How the medications work5
- How do GLP-1 medications actually work? The mechanism behind semaglutide and tirzepatide, explained in terms of appetite signalling rather than metabolism
- Semaglutide or tirzepatide: how do they compare? How the two leading drugs compare on weight, on heart outcomes, and on who each one actually suits
- Is the GLP-1 pill as good as the injection? Where the tablet lands against the injections once you line up the trial results side by side
- Is metformin an alternative to a GLP-1? How metformin performs against newer drugs on weight, and the conditions where it is still a good choice
- Medication or bariatric surgery: how do you choose? The trade offs between an operation and an ongoing prescription, and the thresholds guidelines use to decide
Side effects and safety6
- Which GLP-1 side effects are normal and which are not? Sorting the expected gut symptoms from the ones that need a same day call to a clinician
- How do I manage nausea on a GLP-1? Practical steps that reduce nausea, starting with the escalation schedule most people are pushed through too quickly
- What is the real risk of pancreatitis or gallbladder problems? Which of the two feared complications the trial data actually supports, and which one remains uncertain
- Should the thyroid cancer warning on GLP-1s worry me? Where the boxed warning came from, who it genuinely rules out, and what human data has shown
- Do I need to stop a GLP-1 before pregnancy? Timing rules before a planned pregnancy, and the contraception interaction that catches people out on tirzepatide
- Are compounded semaglutide and tirzepatide safe? The regulatory position after the shortages ended, and the dosing errors regulators have documented in compounded products
Making them work5
- Why has my weight loss stalled on a GLP-1? When the curve is meant to flatten, and which variables are worth reviewing before calling it a failure
- How much muscle do you lose on a GLP-1, and can you protect it? How much of the loss is lean tissue, and the two things that reliably defend against it
- How much protein do I need while losing weight? Protein targets obesity societies now recommend during active weight loss, and why spreading them across meals matters
- Do I have to lift weights while on a GLP-1? Why walking does not count as the muscle protecting stimulus, and what the current advisory asks for instead
- What happens if my GLP-1 becomes unavailable or unaffordable? How to handle a gap in supply, and why switching drugs means starting the escalation over again
Stopping and maintaining3
- How long do you have to stay on a GLP-1? Whether there is an end date, and the comparison with blood pressure treatment that makes the answer clearer
- Is there a lower maintenance dose once I reach my goal? Whether dropping to a lower dose after goal weight is proven practice or simply clinical judgement
- How do you come off a GLP-1 without regaining the weight? What the stopping trials actually show about regain, and how to plan a deliberate exit anyway
Not sure which one you need?
People arrive at this topic from very different positions, and the question that decides the next step is different in each. Find your row first.
| Where you are | The question that actually decides your next step |
|---|---|
| Considering starting | Do you meet the criteria, do you have a contraindication, and has anything else driving weight gain been ruled out first |
| Recently started and feeling awful | Is this expected gastrointestinal adjustment that dose pace and meal size can fix, or a red flag that needs the drug stopped |
| Losing weight steadily | Are protein intake and resistance training in place, since this is the window where lean mass is either protected or lost |
| Weight loss has stalled | Is this a true physiological plateau, an untitrated dose, or under-reported intake returning as appetite recovers |
| At or near your goal | What is the lowest dose that holds the result, and what does maintenance look like as a plan rather than a pause |
| Thinking about stopping | What replaces the appetite regulation the drug was providing, and over what timeframe do you step down |
| Cannot get it or cannot afford it | What is the safest switch or bridge, and what protects the result during a gap in supply |
| Pregnant or planning pregnancy | When to stop, what contraception is needed, and how far ahead of conception the drug should be discontinued |
The answers below are grouped in that order, so read the one matching your row before anything else.
Background: how to think about weight, glp-1s and obesity medicine A longer read from Dr. Sater, for context rather than a specific question
The most common misunderstanding about GLP-1 medicines is that they are weight loss products with a start date and a finish date. Regulators stopped treating them that way some time ago. The FDA approved semaglutide in March 2024 to reduce cardiovascular events in adults with cardiovascular disease and obesity or overweight, approved tirzepatide in December 2024 as the first medication for moderate to severe obstructive sleep apnea in adults with obesity, and granted semaglutide accelerated approval in August 2025 for noncirrhotic MASH with moderate to advanced liver fibrosis. Weight is now one endpoint among several, which changes who should be on one of these drugs and what counts as it working.
What this area actually covers
This is obesity medicine, not a drug category. CDC data from August 2021 to August 2023 put obesity in 40.3 percent of US adults and severe obesity in 9.4 percent. At that scale the clinical question is rarely whether a medication exists that produces weight loss. It is which of several problems a given person actually has, and whether a GLP-1 addresses it.
Three decisions determine how this goes, and only one of them is about which drug. First, whether weight gain here is being driven by something else entirely, such as untreated thyroid disease, obstructive sleep apnea, a psychiatric medication or a corticosteroid. Second, what happens to muscle, protein intake and training while the weight comes off. Third, what the plan is when the drug stops, becomes unaffordable, or runs out at the pharmacy.
Where treatment usually goes wrong
The commonest error is escalating the dose on the printed schedule regardless of what the person is eating. Doses climb, intake collapses, protein falls, nausea is treated as the price of admission, and lean mass goes with the fat. The second error is having no exit plan from the first visit. In the STEP 1 trial extension, published in Diabetes, Obesity and Metabolism in 2022, participants regained 11.6 percentage points of the body weight they had lost by week 120, roughly two thirds of it, and the improvements in cardiometabolic markers moved back toward baseline. Stopping without a structure is not neutral.
What is settled and what is contested
Comparative efficacy is settled. In SURMOUNT-5, published in the New England Journal of Medicine in 2025, tirzepatide reduced body weight by 20.2 percent at 72 weeks against 13.7 percent for semaglutide. Those are group averages and the individual spread around them is wide, so the trial answers which drug is stronger on average and not what any one person will lose. Cardiovascular benefit is also established: in the trial supporting the FDA approval, involving more than 17,600 participants, major adverse cardiovascular events occurred in 6.5 percent on semaglutide against 8.0 percent on placebo.
What remains open is duration, the lowest dose that holds a result, how much muscle loss matters over decades, and compounded copies. On that last point the FDA has issued a declaratory order resolving the semaglutide injection shortage, which removed the shortage basis compounders had relied on. Sellers still marketing compounded versions and the agency are not describing the same legal situation.
What changed recently
The World Health Organization issued its first global guideline on GLP-1 medicines for obesity on 1 December 2025. It is a conditional recommendation for long-term use in adults, excluding pregnancy, and it is candid about limits: WHO states that even with rapid production expansion these therapies will reach fewer than 10 percent of people who could benefit by 2030. Access, not efficacy, is now the binding constraint for most of the world. Options have also widened. An oral 25 mg semaglutide tablet is approved for weight management, and the FDA approved a higher 7.2 mg dose of injectable semaglutide on 19 March 2026.
The answers below are ordered roughly the way the decisions arrive: eligibility and contraindications first, then side effects and dosing, then muscle and protein, then plateaus, maintenance and coming off. Use the table above to find your starting point rather than reading in order.
Other topics
Every answer here is written and reviewed by a board-certified endocrinologist. To have that judgment applied to your own history, book a consultation with Dr. Sater.
Book a consultation